Table 1 Basic characteristics of the included literature
Author | Year | Study period | Region | Study design | Therapy | Time of test | Sample size | Age | TNM stage | PLR cut-off | Outcome | Quality score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ayhan et al. | 2022 | 2008–2018 | Turkey | Retrospective cohort | Surgery | Pretreatment | 163 | 49 | IA2-IIIC2 | 145 | OS, PFS | 7 |
Chen et al. | 2016 | 2006–2009 | China | Retrospective cohort | Surgery | Pretreatment | 407 | 44 | IB1-IIA | 143.47 | OS | 7 |
Chen et al. | 2023 | 2016–2021 | China | Retrospective cohort | Radiochemotherapy | Pretreatment | 138 | 60.1 | IB-IVA | 236 | OS | 7 |
Ferioli et al. | 2023 | 2007–2021 | Italy | Retrospective cohort | Radiochemotherapy | Pretreatment | 173 | 56 | IB-IVA | 210 | OS, DFS | 7 |
Fullerton et al. | 2023 | 1999–2015 | Canada | Retrospective cohort | Radiochemotherapy | Pretreatment | 196 | NA | I-IV | 250 | OS, PFS | 7 |
Gao et al. | 2023 | 2017–2020 | China | Retrospective cohort | Radiotherapy | Baseline | 110 | NA | I-IV | 186.88 | OS, PFS | 7 |
Guo et al. | 2023 | 2014–2017 | China | Retrospective cohort | Surgery | NA | 109 | 53.95 | IA-IIA | 111.96 | OS | 7 |
Haraga et al.[] | 2016 | 2007–2013 | Japan | Retrospective cohort | Radiochemotherapy | Pretreatment | 95 | 61.5 | IB1-IVA | 171 | OS, PFS | 7 |
Haraga et al.[] | 2016 | 2007–2013 | Japan | Retrospective cohort | Radiotherapy | Pretreatment | 36 | 61.5 | IB1-IVA | 171 | OS | 7 |
He et al. | 2018 | 2007–2009 | China | Retrospective cohort | Surgery or radiotherapy plus chemotherapy | Pretreatment | 229 | 44 | I-IV | 149.27 | OS | 7 |
Holub et al. | 2019 | 2009–2016 | Spain | Retrospective cohort | Surgery or radiotherapy plus chemotherapy | Pretreatment | 151 | 52.8 | I-IV | 210 | OS | 8 |
Ida et al. | 2018 | 2004–2015 | Japan | Retrospective cohort | Surgery or radiotherapy plus chemotherapy | Pretreatment | 79 | 52.4 | recurrent advanced | 260 | OS | 7 |
Jiang et al.[] | 2021 | 2009–2017 | China | Retrospective cohort | Surgery or radiotherapy plus chemotherapy | Pretreatment | 501 | 48.88 | IB-IIA | 163.41 | OS, PFS | 8 |
Jiang et al.[] | 2021 | 2009–2017 | China | Retrospective cohort | Surgery or radiotherapy plus chemotherapy | Pretreatment | 82 | 48.88 | IB-IIA | 163.41 | OS | 8 |
Jonska-Gmyrek et al. | 2018 | 2003–2008 | Poland | Retrospective cohort | Surgery or radiotherapy plus chemotherapy | Pretreatment | 94 | 53 | I-IV | 158 | OS | 7 |
Lee et al. | 2017 | 2011–2014 | Korea | Retrospective cohort | Surgery or radiotherapy plus chemotherapy | Pretreatment | 145 | 52 | I-IV | 170 | PFS | 7 |
Lee et al. | 2020 | 2005–2016 | Korea | Retrospective cohort | Radiochemotherapy | Before and after treatment | 125 | 53.67 | IIB-IIIB | NA | OS, PFS | 7 |
Li et al. | 2021 | 2011–2016 | China | Retrospective cohort | Radiochemotherapy | Pretreatment | 260 | 51 | IIB | 154.17 | OS, PFS | 7 |
Li et al. | 2023 | 2009–2014 | China | Retrospective cohort | Radiochemotherapy | Baseline | 795 | 51 | IIB-IVA | 164.29 | OS | 7 |
Medici et al. | 2023 | 2007–2021 | Italy | Retrospective cohort | Radiochemotherapy | Pretreatment | 173 | 56 | IB-IVA | 210 | OS, DFS | 7 |
Nakamura et al. | 2015 | 2005–2014 | Japan | Retrospective cohort | Radiochemotherapy | Pretreatment | 32 | 52.6 | recurrent advanced | 322 | OS | 7 |
Nakamura et al. | 2018 | 1997–2013 | Japan | Retrospective cohort | Radiochemotherapy | Pretreatment | 98 | 65 | I-IV | 212 | OS | 8 |
Nuchpramool et al. | 2018 | 2001–2016 | Tailand | Retrospective cohort | Surgery or radiotherapy plus chemotherapy | Pretreatment | 460 | 47 | IA2-IB1 | 119 | OS, DFS | 8 |
Onal et al. | 2016 | 2006–2014 | Turkey | Retrospective cohort | Radiochemotherapy | Pretreatment | 235 | 57 | IB2-IVA | 133.02 | OS, PFS | 7 |
Thuler et al. | 2021 | 2006–2009 | Brazil | Retrospective cohort | Surgery or radiotherapy plus chemotherapy | Pretreatment | 1266 | 49.8 | I-IV | 146.7 | OS | 7 |
Wang et al. | 2023 | 2013–2015 | China | Retrospective cohort | Radiotherapy | Pretreatment | 178 | 53.85 | IIB-III | 186.67 | OS | 7 |
Zhang et al. | 2018 | 2005–2009 | China | Retrospective cohort | Surgery | Pretreatment | 235 | 46 | IB-IIA | 176.5 | OS, PFS | 7 |
Zhang et al. | 2023 | 2007–2015 | China | Retrospective cohort | Radiochemotherapy | NA | 965 | 53.4 | IIB-IIIB | 174.8 | OS, PFS | 7 |
Zheng et al. | 2016 | 2005–2012 | China | Retrospective cohort | Surgery + Radiochemotherapy | Pretreatment | 795 | 49.5 | IA-IIA | 128.3 | OS, DFS | 7 |
Zhu et al. | 2018 | 2012–2014 | China | Retrospective cohort | Surgery | Pretreatment | 339 | 45 | IA-IIB | 143.79 | OS, PFS | 7 |